AV Favipiravir
K |
|||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA antivirals by mechanism}} | ||
{{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}} | {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}} | ||
Version vom 18. Januar 2021, 20:11 Uhr
| PHA antivirals by mechanism |
32401463 2006. Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
32417899 2020. Favipiravir, an antiviral for COVID-19?
32585765 2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.
32536670 2020. Uric Acid Elevation by Favipiravir, an Antiviral Drug.
32405421 2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?
32353191 2020. Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
